Stock Price
15.20
Daily Change
-34.93%
Yearly
-45.93%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 115.28 -1.61 -1.38% 10.80%
Amgen 198.88 -4.59 -2.26% -11.64%
Ardelyx 1.14 0.28 32.24% -81.40%
Arena Pharmaceuticals 54.49 -0.47 -0.86% -17.58%
Arrowhead Research 70.05 -1.12 -1.57% 11.83%
Bayer 44.52 -0.80 -1.77% -8.54%
Biogen 235.74 -0.37 -0.16% -3.05%
Corcept Therapeutics 21.00 -0.12 -0.57% -8.66%
Curis 4.88 0.04 0.83% 218.95%
Dynavax Technologies 16.15 0.08 0.50% 207.03%
Gilead Sciences 68.93 -1.72 -2.43% 12.78%
Intercept Pharmaceuticals 17.21 0.78 4.75% -51.78%
Infinity Pharmaceuticals 2.17 0.08 3.83% 5.85%
J&J 155.93 -3.82 -2.39% 5.75%
Karyopharm Therapeutics 6.95 0.10 1.46% -58.92%
Novartis 73.56 0.12 0.16% -9.60%
Novavax 208.63 14.67 7.56% 68.97%
Puma Biotechnology 3.10 0.02 0.65% -74.10%
PTC Therapeutics 37.16 0.27 0.73% -40.82%
Regeneron Pharmaceuticals 636.53 -17.87 -2.73% 23.82%
Roche Holding 362.40 2.75 0.76% 20.96%
Spectrum Pharmaceuticals 1.58 0 0% -65.80%
TG Therapeutics 15.20 -8.16 -34.93% -45.93%
Vertex Pharmaceuticals 186.94 -3.17 -1.67% -18.83%
Verastem 2.67 0.08 3.09% 27.75%
Acceleron Pharma 178.75 -0.93 -0.52% 57.43%
Ziopharm Oncology 1.39 0.10 7.75% -51.23%

Indexes Price Day Year
US2000 2199 -43.07 -1.92% 19.76%
NASDAQ 15538 -245.14 -1.55% 25.76%

TG Therapeutics
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).